Postpartum long-acting reversible contraception among privately insured: U.S. National analysis 2007–2016, by term and preterm birth
Contraception · 2023
DOI: 10.1016/j.contraception.2023.110065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contraception, 2023. Verfasst von Jonathan G Shaw und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. Electronic address: jgshaw@stanford.edu. Hauptthemen laut MEDLINE: Long-Acting Reversible Contraception, Premature Birth, Intrauterine Devices. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Stanford University, Robertson Foundation.
Abstract (Originalsprache)
OBJECTIVES: To investigate postpartum long-acting reversible contraception (LARC) use among privately insured women, with specific consideration of use after preterm delivery. STUDY DESIGN: We used the national IBM MarketScan Commercial Database to identify singleton deliveries from 2007 to 2016, spontaneous preterm birth, and follow-up ≤12 weeks postpartum. We assessed ≤12-week postpartum LARC placement overall and after spontaneous preterm deliveries, across study years. We examined timing of placement, rates of postpartum follow-up, and state-level variation in postpartum LARC. RESULTS: Among 3,132,107 singleton deliveries, 6.6% were spontaneous preterm. Over the time period, total postpartum LARC use increased 4.8% to 11.7% for intrauterine devices (IUDs), 0.2% to 2.4% for implants. In 2016, those who experienced a spontaneous preterm birth were less likely to initiate postpartum IUDs compared to their peers (10.2% vs 11.8%, p < 0.001), minimally more likely to initiate implants (2.7% vs 2.4%, p = 0.04) and more likely to present for postpartum care (61.7% vs 55.9%, p < 0.001). LARC placement prior to hospital discharge was rare (preterm: 8 per 10,000 deliveries vs all others: 6.3 per 10,000 deliveries, p = 0.002). State-level analysis showed wide variation in postpartum LARC (range 6%-32%). CONCLUSIONS: While postpartum LARC use increased among the privately insured 2007-2016, few received LARC prior to hospital discharge. Those experiencing preterm birth were no more likely to receive inpatient LARC. Postpartum follow-up remained low and regional variation of LARC was high, highlighting the need for efforts to remove barriers to inpatient postpartum LARC for all who desire it-public and privately insured alike. IMPLICATIONS: Among the half of U.S. births that are privately insured, postpartum LARC is increasing after both term and preterm births, yet exceedingly few (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. Electronic address: jgshaw@stanford.edu.
- Upstream USA, Boston, MA, USA.
- Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
- Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California, USA.
Förderung
- Stanford University
- Robertson Foundation
Zitieren
APA
Shaw, J. G., Goldthwaite, L. M., Marić, I., Shaw, K. A., Stevenson, D. K., & Shaw, G. M. (2023). Postpartum long-acting reversible contraception among privately insured: U.S. National analysis 2007–2016, by term and preterm birth. Contraception. https://doi.org/10.1016/j.contraception.2023.110065
Vancouver
Shaw JG, Goldthwaite LM, Marić I, Shaw KA, Stevenson DK, Shaw GM. Postpartum long-acting reversible contraception among privately insured: U.S. National analysis 2007–2016, by term and preterm birth. Contraception. 2023. doi:10.1016/j.contraception.2023.110065
BibTeX
@article{Shaw2023,
author = {Shaw, Jonathan G and Goldthwaite, Lisa M and Marić, Ivana and Shaw, Kate A and Stevenson, David K and Shaw, Gary M},
title = {Postpartum long-acting reversible contraception among privately insured: U.S. National analysis 2007–2016, by term and preterm birth},
journal = {Contraception},
year = {2023},
doi = {10.1016/j.contraception.2023.110065}
}
EUVIMED